Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2019, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline landscape.
Marburg hemorrhagic fever is a rare, acute infectious which affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain and weight loss.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 17, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 2 and 2 molecules, respectively.
Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Overview
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Companies Involved in Therapeutics Development
ANP Technologies Inc
BioCryst Pharmaceuticals Inc
Collaborations Pharmaceuticals Inc
Eisai Co Ltd
Emergent BioSolutions Inc
Emergex Vaccines Ltd
Fab’entech SA
Fox Chase Chemical Diversity Center Inc
GeoVax Labs Inc
Greffex Inc
IDBiologics Inc
Immunomodulation Inc
Integrated BioTherapeutics Inc
Intervir Therapeutics
Johnson & Johnson
Mapp Biopharmaceutical Inc
NanoViricides Inc
Phoenix Biotechnology Inc
Profectus BioSciences Inc
Rodos BioTarget GmbH
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drug Profiles
(Ebola + Marburg) (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Ebola + Marburg) (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANP-803 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies for Ebola and Marburg Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARD-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eritoran tetrasodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FDX-000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galidesivir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GEOEM-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GreEMTri - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hemorrhagic fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infectious disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
marburg vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBP-091 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MR-78 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-05204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBT-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 for Marburgvirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 for Marburgvirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Ebola and Marburg Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit VP40 for Ebola and Marburg Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SW-456 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tilorone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAC-69120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Product Development Milestones
Featured News & Press Releases
Nov 12, 2019: IAVI announces award from U.S. Department of Defense to advance Marburg Virus Vaccine candidate development
Jul 29, 2019: GeoVax announces 100% protection data from Marburg Virus Vaccine Study
Jun 11, 2019: MappBio announces contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure
May 09, 2019: BioCryst completes Phase 1 clinical trial of galidesivir
Mar 05, 2019: HHS' BARDA funds its first Marburg virus vaccine development
Jan 02, 2019: BioCryst initiates phase 1 clinical trial of Galidesivir
Jan 10, 2018: TSRI scientists discover workings of first promising Marburg virus treatment
Sep 28, 2017: New Research Indicates Expanded Potential Uses For Phoenix Biotech Drug PBI-05204: Inhibits Ebola and Marburg Viruses and Offers Novel Treatment Approaches For Alzheimer's and Parkinson's Diseases
Apr 05, 2017: Emergex Multivalent Filovirus vaccine Awarded SBRI Contract by Innovate UK
Jan 19, 2016: Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial
Nov 17, 2015: Profectus Presents Preclinical Data Demonstrating that a Single Dose of Multi-Component Vaccine Provides Complete Protection Against Zaire and Sudan Species of Ebola Virus and Marburg Virus
Apr 08, 2015: Profectus BioSciences Ebola Vaccine Shown Effective and Safe in Providing Rapid, Single-Dose Protection Against Current "Makona" Ebola Outbreak Strain in Non-Human Primates
Mar 31, 2015: BioCryst Awarded BCX4430 Advanced Development Contract
Mar 25, 2015: IBT Presents Pan-Ebola and Pan-Filovirus Monoclonal Antibodies
Jan 22, 2015: NanoViricides Reports That It Has Shipped anti-Ebola Drug Candidates For Testing to a BSL-4 Hi-Security Biocontainment Laboratory
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 6: Products under Development by Universities/Institutes, H2 2019
Table 7: Number of Products by Stage and Target, H2 2019
Table 8: Number of Products by Stage and Mechanism of Action, H2 2019
Table 9: Number of Products by Stage and Route of Administration, H2 2019
Table 10: Number of Products by Stage and Molecule Type, H2 2019
Table 11: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by ANP Technologies Inc, H2 2019
Table 12: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2019
Table 13: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Collaborations Pharmaceuticals Inc, H2 2019
Table 14: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Eisai Co Ltd, H2 2019
Table 15: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, H2 2019
Table 16: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Emergex Vaccines Ltd, H2 2019
Table 17: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Fab’entech SA, H2 2019
Table 18: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Fox Chase Chemical Diversity Center Inc, H2 2019
Table 19: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, H2 2019
Table 20: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Greffex Inc, H2 2019
Table 21: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by IDBiologics Inc, H2 2019
Table 22: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Immunomodulation Inc, H2 2019
Table 23: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Integrated BioTherapeutics Inc, H2 2019
Table 24: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Intervir Therapeutics, H2 2019
Table 25: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Johnson & Johnson, H2 2019
Table 26: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Mapp Biopharmaceutical Inc, H2 2019
Table 27: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by NanoViricides Inc, H2 2019
Table 28: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Phoenix Biotechnology Inc, H2 2019
Table 29: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Profectus BioSciences Inc, H2 2019
Table 30: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Rodos BioTarget GmbH, H2 2019
Table 31: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects, H2 2019
Table 32: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products, H2 2019
List of Figures
Figure 1: Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
